Frontotemporal dementia
MONDO:0017276Frontotemporal dementia (FTD) comprises a group of neurodegenerative disorders, characterized by progressive changes in behavior, executive dysfunction and language impairment, as a result of degeneration of the medial prefrontal and frontoinsular cortices. Four clinical subtypes have been identified: semantic dementia, progressive non-fluent aphasia, behavioral variant FTD and right temporal lobar atrophy.
Also known as: FTD, MSTD, frontotemporal lobe dementia (FLDEM)
178 clinical trials for this condition and its sub-types, 132 tagged with Frontotemporal dementia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Frontotemporal dementia
-
GRN-related frontotemporal lobar degeneration with Tdp43 inclusions 6 trials · 47 incl. sub-types
1 sub-type
- Progressive non-fluent aphasia 24 trials · 44 incl. sub-types Sub-types →
-
Behavioral variant of frontotemporal dementia 22 trials · 42 incl. sub-types
3 sub-types
-
Pick disease 35 trials
-
Inclusion body myopathy with Paget disease of bone and frontotemporal dementia 1 trial · 3 incl. sub-types
4 sub-types
- Inclusion body myopathy with Paget disease of bone and frontotemporal dementia type 1 2 trials
- Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2 1 trial
- Inclusion body myopathy and brain white matter abnormalities 0 trials
- Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 3 0 trials
Most studied deeper sub-types
-
Hope for genetic dementia: AL001 trial ends early
Disease control Stopped earlyThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Sep 21, 2026 17:00 UTC
-
Spinal injection drug targets genetic cause of ALS and dementia
Disease control Stopped earlyResearchers are testing repeated doses of an experimental drug called WVE-004 in adults who have ALS, frontotemporal dementia, or both, linked to a mutation in the C9orf72 gene. Participants receive the drug by spinal injection every 12 weeks for up to 96 weeks. The study tracks …
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control Stopped earlyThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief Stopped earlyThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a synthetic cannabinoid calm agitation in frontotemporal dementia?
Symptom relief Stopped earlyThis phase 2 trial tests whether nabilone, a synthetic cannabinoid, can reduce agitation in people with frontotemporal dementia (FTD). Participants receive both nabilone and a placebo in random order to compare effects. The study includes adults with behavioral variant FTD or pri…
Phase 2 • Sponsor: Simon Ducharme, MD • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief Stopped earlyThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief Stopped earlyThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief Stopped earlyThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Brain scans reveal why dementia changes personality
Knowledge-focused Stopped earlyThis study investigates how Alzheimer's disease and frontotemporal dementia alter a person's sense of self and ability to understand others. Researchers will compare patients with healthy older adults using questionnaires and brain imaging. The goal is to link changes in self-awa…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC